Healthcare ❯Pharmaceuticals ❯Drug Approval

FDA

Bristol Myers Squibb New Drug Mechanisms Neffy Clinical Trials Esketamine SPRAVATO Johnson & Johnson

FDA Approves First Standalone Nasal Spray for Treatment-Resistant Depression

Johnson & Johnson's Spravato becomes the first monotherapy for adults with major depressive disorder unresponsive to oral antidepressants.

FDA Approves First Nasal Spray for Treatment-Resistant Depression

FDA Approves Neffy, the First Needle-Free Epinephrine Nasal Spray for Anaphylaxis